News

Theravance Biopharma, Inc. and Mylan MYL recently announced the commencement of a new phase III clinical program to evaluate revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) being developed to treat chronic obstructive pulmonary disease (COPD). The Phase III clinical program involves two replicate, randomized, placebo-controlled, double-blind, parallel-group,…

Minnesota Health Solutions Corporation (MHS) recently announced a partnership with Novu, an SaaS-based consumer engagement platform designed to align consumers and the health care ecosystem. The partnership will provide a digitally-delivered program to motivate and monitor patients with Chronic Obstructive Pulmonary Disorder (COPD), a condition which, along with all chronic lower respiratory…

Prescribing bronchodilators for patients with chronic obstructive pulmonary disease (COPD) with varying levels of disease severity can be a difficult task for clinicians and healthcare professionals. Of late, several combinations of bronchodilators were approved for patient use in COPD and other respiratory diseases. In a recent article entitled “Comparative efficacy of…

The use of short-acting-beta-2-agonists (SABA) has been associated with prediction of increased risks of chronic obstructive pulmonary disease (COPD) exacerbations in patients, according to a recent study entitled “Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease” published in…

ieCrowd™ recently announced the achievement of a crucial milestone in the commercial advancement of Smart Oxygen, the firm’s supplemental oxygen delivery device. The Smart Oxygen device is being advanced by ieCrowd’s subsidiary Smart Oxygen Solutions and has the ability to automatically adjust to the patient’s need for oxygen, even if those demands are constantly changing, through analyzing the level of…

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by progressive breathlessness, acute exacerbations, increased coughing, mucus, and a feeling of tightness in patients’ chest. Usually if the exacerbation symptoms are not detected and treated on time, they can escalate, leading to a more acute scenario, which can diminish…

In a recent article published in the Polish Archives of Internal Medicine, Richard ZuWallack from the Department of Pulmonary and Critical Care, St. Francis Hospital and Medical Center in Hartford, Connecticut conducted a review exploring the concept of physical activity in patients with Chronic Obstructive Pulmonary Disease.

In a new study entitled “Defining the Asthma-COPD overlap syndrome in a COPD cohort,” authors show that using clinical asthma features is an effective diagnosis strategy to identify patients with asthma–chronic obstructive pulmonary disease (COPD) overlapping syndrome (ACOS). The study was published in the journal…

CSL Behring, a global leader in the plasma protein therapeutics industry, has just announced its breakthrough maintenance treatment for patients with emphysema with documented severe A1-PI deficiency (AATD). Respreeza® has received marketing authorization in all states in the European Union (EU). Respreeza is a highly purified Alpha-1 protein derived from human plasma…

Chronic Obstructive Pulmonary Disease (COPD) includes a group of progressive lung diseases such as emphysema, chronic bronchitis, non-reversible asthma, and some forms of bronchiectasis. COPD typically manifests itself in individuals who have had a long-term contact with harmful pollutants,a history of smoking, or who have a genetic predisposition to the disease. According to the…